| 51 |
23229229 | In vitro inhibitory profile of NDGA against AChE and its in silico structural modifications based on ADME profile. | 2013 Mar |
2 |
| 52 |
23408070 | Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. | 2013 Apr |
2 |
| 53 |
23557940 | The effect of rivastigmine on the LPS-induced suppression of GnRH/LH secretion during the follicular phase of the estrous cycle in ewes. | 2013 May |
2 |
| 54 |
23610582 | Third degree atrioventricular block associated with treatment with rivastigmine transdermal patch. | 2013 Mar |
1 |
| 55 |
23672025 | [Design, synthesis and cholinesterase inhibitory activity of quinoline-polyamine conjugates]. | 2013 Feb |
1 |
| 56 |
23782591 | Medication adherence and tolerability of Alzheimer's disease medications: study protocol for a randomized controlled trial. | 2013 May 4 |
1 |
| 57 |
24081314 | Drugs for cognitive loss and dementia. | 2013 Oct |
2 |
| 58 |
24291871 | [Development of therapies for Alzheimer's disease based on cholinergic hypothesis-status quo and future directions]. | 2013 |
1 |
| 59 |
22323348 | aChE and BuChE inhibition by rivastigmin have no effect on peripheral insulin resistance in elderly patients with Alzheimer disease. | 2012 Feb |
3 |
| 60 |
22451057 | Development of a capillary electrophoresis-mass spectrometry method for the determination of rivastigmine in human plasma--optimization of the limits of detection and quantitation. | 2012 Feb |
1 |
| 61 |
22751086 | Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophrenia. | 2012 Jul-Aug |
1 |
| 62 |
21624391 | Low dose, short-term rivastigmine administration does not affect neurocognition in methamphetamine dependent individuals. | 2011 Sep |
1 |
| 63 |
20190429 | Development of an efficient therapeutic agent for Alzheimer's disease: design and synthesis of dual inhibitors of acetylcholinesterase and serotonin transporter. | 2010 Mar |
1 |
| 64 |
20193764 | Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review. | 2010 Jun |
1 |
| 65 |
20452337 | Galangin, a flavonol derived from Rhizoma Alpiniae Officinarum, inhibits acetylcholinesterase activity in vitro. | 2010 Sep 6 |
2 |
| 66 |
21389938 | [Efficacy and safety of rivastigmine (exelon) in the confusion syndrome in the acute phase of ischemic stroke]. | 2010 |
1 |
| 67 |
22778810 | Selective acetylcholinesterase inhibitor activated by acetylcholinesterase releases an active chelator with neurorescuing and anti-amyloid activities. | 2010 Nov 17 |
2 |
| 68 |
18729824 | Accommodation of physostigmine and its analogues by acetylcholinesterase is dominated by hydrophobic interactions. | 2009 Jan 1 |
1 |
| 69 |
18780301 | Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer's disease and relationships with response to treatment with Donepezil and Rivastigmine. | 2009 Jun 5 |
2 |
| 70 |
19199870 | Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. | 2009 Feb |
4 |
| 71 |
18155915 | Facile synthesis of new carbon-11 labeled conformationally restricted rivastigmine analogues as potential PET agents for imaging AChE and BChE enzymes. | 2008 Apr |
4 |
| 72 |
18207225 | The acetylcholinesterase inhibitor rivastigmine does not alter total choices for methamphetamine, but may reduce positive subjective effects, in a laboratory model of intravenous self-administration in human volunteers. | 2008 Apr |
2 |
| 73 |
18248689 | Evaluation of the cardiovascular and subjective effects of rivastigmine in combination with methamphetamine in methamphetamine-dependent human volunteers. | 2008 Sep |
2 |
| 74 |
18692909 | Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine. | 2008 Oct 15 |
2 |
| 75 |
17134713 | Characterization of reversible and pseudo-irreversible acetylcholinesterase inhibitors by means of an immobilized enzyme reactor. | 2007 Mar 9 |
1 |
| 76 |
17303332 | Modulation of human motor cortex excitability by the cholinesterase inhibitor rivastigmine. | 2007 Mar 19 |
1 |
| 77 |
17355738 | Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits. | 2007 Mar |
2 |
| 78 |
17572053 | [Lewy body dementia and Parkinson disease dementia]. | 2007 Oct |
1 |
| 79 |
17660172 | Effect of rivastigmine on regional cerebral blood flow in Alzheimer's disease. | 2007 May-Jun |
1 |
| 80 |
17724973 | [Acetylcholinesterase inhibitors for dementia--an update]. | 2007 May 21 |
1 |
| 81 |
17955784 | [Are anti-dementia drugs worthwhile?]. | 2007 Sep 13 |
1 |
| 82 |
18042006 | An update on the pharmacology of galantamine. | 2007 Dec |
1 |
| 83 |
18044073 | Rivastigmine in the treatment of Alzheimer's disease: an update. | 2007 |
6 |
| 84 |
16181792 | Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study. | 2006 Jan 15 |
1 |
| 85 |
16373816 | Case of the month: rivastigmine (Exelon) toxicity with evidence of respiratory depression. | 2006 Jan |
1 |
| 86 |
16574032 | Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. | 2006 Mar |
1 |
| 87 |
16797163 | Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation. | 2006 Jul |
1 |
| 88 |
17047484 | Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease. | 2006 Nov |
1 |
| 89 |
15659242 | Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years. | 2005 Jan 19 |
1 |
| 90 |
16024879 | Neurophysiological predictors of long term response to AChE inhibitors in AD patients. | 2005 Aug |
2 |
| 91 |
16144975 | Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors. | 2005 Dec |
3 |
| 92 |
16212945 | Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles. | 2005 Oct 26 |
3 |
| 93 |
16307702 | Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease. | 2005 Nov |
4 |
| 94 |
15132713 | Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. | 2004 |
1 |
| 95 |
15161118 | Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study. | 2004 Apr |
3 |
| 96 |
15163283 | Rivastigmine in vascular dementia. | 2004 Jun |
1 |
| 97 |
15222774 | What are the treatment options for patients with severe Alzheimer's disease? | 2004 |
1 |
| 98 |
15304241 | Acetylcholinesterase inhibitors: novel activities of old molecules. | 2004 Oct |
2 |
| 99 |
15486516 | Rivastigmine augmentation in the management of chronic schizophrenia with comorbid dementia: an open-label study investigating effects on cognition, behaviour and activities of daily living. | 2004 Nov |
1 |
| 100 |
15537349 | Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues. | 2004 Nov 18 |
2 |